Clinical Trial Update: An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen) [Phase 1, Phase 2]

View source ↗

Summary

Open-label extension study of vesleteplirsen (SRP-5051) in Duchenne muscular dystrophy participants has terminated; results from the study were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Vesleteplirsen (vesleteplirsen)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Muscular Dystrophy, Duchenne | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-09-19